Almagate pharma grade API is a crystalline layered double hydroxide of aluminium and magnesium with carbonate as the interlayer anion. The pharmacopoeial substance is described by the simplified formula Al₂Mg₆(OH)₁₄(CO₃)₂·4H₂O, is assigned CAS 66827-12-1, and has a theoretical molecular weight of 629.8 g/mol. The material is supplied as a white to off-white, odourless, practically tasteless crystalline powder and is intended for oral solid dosage forms, oral suspension granules, and controlled aseptic processing for injectable preparations. Almagate is not a physical mixture of aluminium hydroxide and magnesium hydroxide; it is a single crystalline phase in which the carbonate anion occupies the interlayer gallery. This structural organisation produces a more reproducible acid-neutralisation profile in simulated gastric fluid and reduces batch-to-batch variability observed with co-dried binary antacid gels. Two comminution models are available: a fine-grade API with laser diffraction D50 of 8–22 µm for suspension and wet granulation, and a direct-compression grade with D50 of 45–80 µm for tablet and capsule filling.

The powder is non-hygroscopic below 60% relative humidity. Above 65% relative humidity, water is adsorbed reversibly into the layered structure, and drying at 105 °C to constant weight is required before assay, processing, or terminal sterilisation. The API is practically insoluble in water and ethanol, and it displays platy particle morphology with loose bulk density typically between 0.35 g/mL and 0.65 g/mL. The direct-compression grade is densified to reduce fines and improve hopper discharge behaviour on rotary tablet presses.

Which Release Specifications Establish Conformance for Almagate API?

Release acceptance is based on acid-neutralising capacity, metal stoichiometry, carbonate content, loss on drying, and particulate/microbial quality. Acid-neutralising capacity is determined by USP <301>; the dried substance acceptance range is typically 25.0–28.5 mEq/g. Aluminium and magnesium are quantified by inductively coupled plasma optical emission spectrometry after acid digestion, with aluminium controlled at 8.0–10.0% and magnesium at 22.0–25.0% on the dried basis. Carbonate is released by acid decomposition and measured by gas volumetric or gravimetric procedure; the acceptance range is 17.0–21.0% as CO₃²⁻. Loss on drying after 4 h at 105 °C is controlled at ≤10.0%. Identity is confirmed by infrared absorption against the reference spectrum, and powder X-ray diffraction may be used to verify the carbonate interlayer reflection when differentiation from magaldrate is required.

The carbonate interlayer is a critical release parameter because partial replacement by atmospheric moisture or excessive vacuum drying can alter acid-neutralisation kinetics. Batches exposed to high-humidity conditions above 65% RH should be re-dried in a fluid-bed dryer with inlet air dew point below -20 °C before compression. Powder flow is evaluated with a Jenike shear cell or a standard funnel method; the direct-compression grade typically flows through a 10 mm funnel at 8–12 s per 100 g, although this value is sensitive to storage humidity and fines content.

On production-scale tablet lines, the direct-compression grade is blended with microcrystalline cellulose and crospovidone for 15 min in a bin blender at 10 rpm before addition of magnesium stearate. Lubricant levels above 1.0 wt% can delay disintegration because of hydrophobic film formation on the platy particle surface. Tablets compressed to hardness of 80–120 N on a rotary press at 30–60 rpm disintegrate within 15 min in 0.1 M HCl at 37 °C when crospovidone is present at 2.0–4.0 wt%. For high-speed capsule filling, fill weight variation exceeding 4% RSD is an operational boundary for the direct-compression grade; in that case, wet granulation with a 5% povidone K30 binder solution in a 600 L high-shear mixer produces granules with final loss on drying of 2.0–4.0% after fluid-bed drying at 50 °C. The fine grade is suspended in purified water at 8–10% solids for antacid sachets, with viscosity normally below 150 mPa·s at 20 °C when no carbomer is added.

When Almagate Replaces Magaldrate or Sodium Bicarbonate in Acid-Neutralising Formulations

Substitution is not 1:1 by mass because acid-neutralising capacity and ion-release behaviour differ. Sodium bicarbonate provides 11.9 mEq/g theoretical neutralising capacity but releases carbon dioxide rapidly and contributes 274 mg sodium per gram. Magaldrate contains sulfate as the interlayer anion and is commonly cited at 25–27 mEq/g; almagate with carbonate intercalation provides comparable capacity without sulfate release. The kinetic difference is process-relevant: almagate exchanges carbonate for chloride and phosphate gradually in acidic media, giving flatter neutralisation and less rapid gas release than bicarbonate formulations. A unit dose of 500 mg almagate is prepared with 20–30 mL water for oral administration, while sodium bicarbonate-based products require higher mass and produce immediate gas evolution that can disturb gastric emptying assessments.

The replacement decision is governed by the neutralisation requirement per unit dose and the ionic content of the finished formulation. Almagate is preferred when sodium intake is restricted or when sulfate release is undesirable. It is not a direct kinetic substitute for sodium bicarbonate in rapid-acid-neutralisation protocols because the layered double hydroxide shows slower onset and longer plateau. Formulators changing from magaldrate should re-run the acid-neutralising capacity assay and not assume identical mass-based dosing; the carbonate interlayer also influences compressibility and moisture sensitivity differently from sulfate-containing magaldrate.

Particle Size Distribution, Powder Flow, and Terminal Sterilisation Constraints

Fine-grade almagate has a nitrogen BET specific surface area commonly between 50 m²/g and 90 m²/g. The direct-compression grade is densified to 0.55–0.75 g/mL bulk density and contains lower fines content, which improves flow but requires longer disintegration time if tablet porosity is too low. Moisture sorption at 25 °C and 60% RH is below 2.0% mass gain, while at 75% RH the interlayer water uptake may reach 6–10%. Dryers with controlled dew point below -20 °C are required for injectable-grade milling to prevent partial rehydration of the carbonate interlayer before aseptic filling.

For injectable processing, almagate is practically insoluble and cannot be filtered as a true solution. Injectable use therefore means a sterile suspension or a reconstituted powder for suspension, not an intravenous solution. Terminal sterilisation of almagate suspensions by moist heat at 121 °C for 15 min can alter suspension rheology and particle aggregation; published data for this specific configuration is limited, and viscosity drift should be measured at 40 °C/75% RH over 6 months in development stability studies. Bacterial endotoxins are controlled to <0.5 EU/mg by Ph. Eur. 2.6.14, and sub-visible particle counts should meet Ph. Eur. 2.9.19 for parenteral suspensions. The material should not be combined with phosphate-containing buffers in injectable preparations because the anion-exchange capacity of the layered double hydroxide removes phosphate from solution and forms insoluble aluminium phosphate. In oral granules, the same anion-exchange property can bind phosphate in the gastrointestinal tract; therefore, prolonged high-dose administration should be assessed for serum phosphate changes.

Almagate is incompatible with strongly acidic solutions during compounding except for the intended acid-neutralisation reaction. It should be stored in closed containers at 15–25 °C, protected from humidity above 60% RH, and not exposed to open steam or condensing water during transfer. For direct-compression operations, bin blender discharge should be checked for ratholing and arching; if flow stalls, a vibratory hopper or forced-discharge feeder set below 20 Hz is used instead of increasing lubricant content, which would delay disintegration.